摘要
目的:探讨不同MTHFR基因型对叶酸降低同型半胱氨酸(Hcy)水平的影响。方法:收集郑州大学第一附属医院收治的老年冠心病(CHD)患者180例,随机分为2组,叶酸治疗组91例(叶酸5 mg/d)及对照组89例(未应用叶酸),观察8周后2组血浆Hcy的变化,并按MTHFR677 CC、CT及TT基因型作分层分析。结果:基线水平3种基因型血浆Hcy差异有统计学意义(P<0.001),TT基因型血浆Hcy最高。CC与CT基因型间血浆Hcy差异无统计学意义(P=0.057)。用药8周后叶酸治疗组TT基因型血浆Hcy下降幅度最大约24%,CC、CT基因型血浆Hcy下降分别为6%和15%。对照组8周后CC、CT、TT基因型血浆Hcy均略下降。结论:老年CHD患者不同MTHFR基因型血浆Hcy有差异,TT基因型血浆Hcy最高。叶酸可以降低老年CHD患者血浆Hcy水平,TT基因型获益最大。
Objective To investigate the impact of methylene tetrahydrofolate reductase （MTHFR） gene polymorphism on folicacid for lowering plasma level of homocysteine in elderly patients with coronary heart disease （CHD）. Methods In the first affiliated hospital of Zhengzhou university, a total of 180 elderly patients with CHD were randomized to two groups. The study group （91 ptients） received folicacid 5mg once daily and the control group （89 patients） received no folio acid. 8 weeks after treatment, the changes in plasma Hey were observed and analyzed by MTHFR genotypes （TF vs. CC vs. CT）. Results Plasma Hcy of the three genotypes had a statistical significance at the baseline （P 〈 0.001 ）, among which plasma Hcy level was the hightest in patients with genotype TT, while it had on difference in genotypes CC and CT （P = 0.057）. 8 weeks after treatment, plasma Hey level declined up to 24% in the patients with genotype TT in the study group, while it decreased about 6% and 15% in patients with genotype CC or CT, separately. Hcy level was slightly decreased in the patients with genotype CC, CT, or TTin the control group. Conclusions Plasma Hey level differs statistically in three genotypes, and it is the highest in genotyp TI＇. Folicacid can effectively lower the level of plasma Hey in elderly patients with CHD, especially those with genotype TT.
出处
《实用医学杂志》
CAS
北大核心
2014年第7期1091-1093,共3页
The Journal of Practical Medicine
关键词
冠心病
亚甲基四氢叶酸还原酶
同型半胱氨酸
叶酸
Coronary disease
Methylene tetrahydrofolate reductase
Homocysteine
Folic acid
